In this open-label , phase II study , patients with resected stage IIIA-N@ NSCLC harbouring EGFR mutations ( either exon @ deletion or L@R point mutation ) were assigned randomly to receive pemetrexed ( @mg/m ( @ ) ) and carboplatin ( AUC = @ ) , administered every @days for @ cycles , followed with or without gefitinib ( @mg/day ) for @months .